U.S. drugmaker Pfizer Inc on Tuesday forecast 2016 revenue and earnings below analysts' estimates, largely because of the strong dollar.
The company's shares fell 1.5 percent to $29.70 even though soaring Prevnar pneumonia vaccine sales led to a stronger-than-expected fourth quarter.
Pfizer forecast 2016 revenue of $49 billion to $51 billion, up from $48.9 billion in 2015 but shy of Wall Street expectations of $52.49 billion.
The company's forecasts do not include the planned purchase of Allergan in the second half of the year.
Revenue rose 7 percent to $14.05 billion in the fourth quarter, ahead of the average analyst estimate of $13.56 billion, according to Thomson Reuters.
